

Ilias Karaiskos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3461304/publications.pdf>

Version: 2024-02-01

60
papers

4,362
citations

126907

33
h-index

118850

62
g-index

66
all docs

66
docs citations

66
times ranked

4471
citing authors

#	ARTICLE	IF	CITATIONS
1	Carbapenemase producing <i>Klebsiella pneumoniae</i> : implication on future therapeutic strategies. Expert Review of Anti-Infective Therapy, 2022, 20, 53-69.	4.4	25
2	How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?. Expert Opinion on Pharmacotherapy, 2022, 23, 5-8.	1.8	4
3	Pulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and formed colistin following nebulisation of CMS among patients with ventilator-associated pneumonia. International Journal of Antimicrobial Agents, 2022, 59, 106588.	2.5	7
4	A Wide Database for a Multicenter Study on Pneumocystis jirovecii Pneumonia in Intensive Care Units. Studies in Health Technology and Informatics, 2022, , .	0.3	1
5	Emergence of ceftazidime-avibactam resistance through distinct genomic adaptations in KPC-2-producing <i>Klebsiella pneumoniae</i> of sequence type 39 during treatment. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 219-224.	2.9	26
6	Ceftazidime/avibactam in the era of carbapenemase-producing <i>Klebsiella pneumoniae</i> : experience from a national registry study. Journal of Antimicrobial Chemotherapy, 2021, 76, 775-783.	3.0	51
7	Performance of Existing Definitions and Tests for the Diagnosis of Invasive Fungal Diseases other than Invasive Candidiasis and Invasive Aspergillosis in Critically Ill, Adult Patients: A Systematic Review with Qualitative Evidence Synthesis. Journal of Fungi (Basel, Switzerland), 2021, 7, 176.	3.5	3
8	Multidrug-resistant <i>Klebsiella pneumoniae</i> : mechanisms of resistance including updated data for novel β -lactam- β -lactamase inhibitor combinations. Expert Review of Anti-Infective Therapy, 2021, 19, 1457-1468.	4.4	28
9	Anterolateral Minimally Invasive Total Hip Arthroplasty: Pitfalls During the Learning Curve and Clinical Outcomes. Májica, 2021, 16, 394-399.	0.1	5
10	Evaluation of in vitro methods for testing tigecycline combinations against carbapenemase-producing <i>Klebsiella pneumoniae</i> isolates. Journal of Global Antimicrobial Resistance, 2020, 20, 98-104.	2.2	2
11	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 2852-2863.	3.0	14
12	De-escalation of antimicrobial therapy in ICU settings with high prevalence of multidrug-resistant bacteria: a multicentre prospective observational cohort study in patients with sepsis or septic shock. Journal of Antimicrobial Chemotherapy, 2020, 75, 3665-3674.	3.0	21
13	Polymyxin Triple Combinations against Polymyxin-Resistant, Multidrug-Resistant, KPC-Producing <i>Klebsiella pneumoniae</i> . Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	13
14	Carbapenem-Sparing Strategies for ESBL Producers: When and How. Antibiotics, 2020, 9, 61.	3.7	88
15	Stewardship of Antibiotics for Multidrug-Resistant Gram-Negative Bacteria. Antibiotics, 2020, 9, 206.	3.7	3
16	In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR <i>Pseudomonas aeruginosa</i> isolates from Greece. Journal of Antimicrobial Chemotherapy, 2020, 75, 2164-2172.	3.0	13
17	Outbreak of KPC-2-producing <i>Klebsiella pneumoniae</i> endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019. Eurosurveillance, 2020, 25, .	7.0	31
18	ColistinDose, a Mobile App for Determining Intravenous Dosage Regimens of Colistimethate in Critically Ill Adult Patients: Clinician-Centered Design and Development Study. JMIR MHealth and UHealth, 2020, 8, e20525.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Multifaceted mechanisms of colistin resistance revealed by genomic analysis of multidrug-resistant <i>Klebsiella pneumoniae</i> isolates from individual patients before and after colistin treatment. <i>Journal of Infection</i> , 2019, 79, 312-321.	3.3	24
20	International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). <i>Pharmacotherapy</i> , 2019, 39, 10-39.	2.6	545
21	The "Old" and the "New" Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How. <i>Frontiers in Public Health</i> , 2019, 7, 151.	2.7	198
22	Oral fosfomycin for the treatment of chronic bacterial prostatitis. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1430-1437.	3.0	41
23	Nationwide epidemiology of carbapenem resistant <i>Klebsiella pneumoniae</i> isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance. <i>BMC Infectious Diseases</i> , 2019, 19, 167.	2.9	68
24	In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing <i>Klebsiella pneumoniae</i> isolated in Greek hospitals in 2015-2016. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019, 38, 1143-1150.	2.9	37
25	Novel β -lactam- β -lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 133-149.	3.3	67
26	Comparison of Predictors and Mortality Between Bloodstream Infections Caused by ESBL-Producing <i>Escherichia coli</i> and ESBL-Producing <i>Klebsiella pneumoniae</i> . <i>Infection Control and Hospital Epidemiology</i> , 2018, 39, 660-667.	1.8	49
27	Management of KPC-producing <i>Klebsiella pneumoniae</i> infections. <i>Clinical Microbiology and Infection</i> , 2018, 24, 133-144.	6.0	136
28	Multifactorial chromosomal variants regulate polymyxin resistance in extensively drug-resistant <i>Klebsiella pneumoniae</i> . <i>Microbial Genomics</i> , 2018, 4, .	2.0	39
29	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 577-585.	2.5	36
30	Evaluation of ComASP, Colistin (formerly SensiTest, Colistin), a commercial broth microdilution-based method to evaluate the colistin minimum inhibitory concentration for carbapenem-resistant <i>Klebsiella pneumoniae</i> isolates. <i>Journal of Global Antimicrobial Resistance</i> , 2018, 15, 123-126.	2.2	9
31	Epidemiology and resistance phenotypes of carbapenemase-producing <i>Klebsiella pneumoniae</i> in Greece, 2014 to 2016. <i>Eurosurveillance</i> , 2018, 23, .	7.0	59
32	Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing <i>Klebsiella pneumoniae</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2017, 36, 1305-1315.	2.9	49
33	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 726-734.	9.1	367
34	Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study. <i>International Journal of Antimicrobial Agents</i> , 2017, 50, 664-672.	2.5	8
35	Combination therapy for extensively-drug resistant gram-negative bacteria. <i>Expert Review of Anti-Infective Therapy</i> , 2017, 15, 1123-1140.	4.4	37
36	Colistin: still a lifesaver for the 21st century?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 59-71.	3.3	91

#	ARTICLE	IF	CITATIONS
37	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. <i>Clinical Infectious Diseases</i> , 2017, 65, 1615-1623.	5.8	43
38	Point-prevalence survey of healthcare facility-onset healthcare-associated <i>Clostridium difficile</i> infection in Greek hospitals outside the intensive care unit: The C. DEFINE study. <i>PLoS ONE</i> , 2017, 12, e0182799.	2.5	8
39	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4159-4169.	3.2	137
40	A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1362-1371.	3.0	89
41	Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. <i>International Journal of Antimicrobial Agents</i> , 2016, 48, 337-341.	2.5	28
42	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1672-1680.	3.0	41
43	Nationwide surveillance of resistance rates of <i>Staphylococcus aureus</i> clinical isolates from Greek hospitals, 2012–2013. <i>Infectious Diseases</i> , 2016, 48, 287-292.	2.8	11
44	High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 90-93.	2.5	46
45	Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6471-6476.	3.2	59
46	Plazomicin: an investigational therapy for the treatment of urinary tract infections. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 1501-1511.	4.1	35
47	Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 7240-7248.	3.2	93
48	Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. <i>International Journal of Antimicrobial Agents</i> , 2014, 43, 52-59.	2.5	188
49	Large vessel vasculitis in a patient with acute Q-fever: A case report. <i>IDCases</i> , 2014, 1, 56-59.	0.9	14
50	Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1351-1370.	1.8	259
51	Nosocomial dissemination of <i>Providencia stuartii</i> isolates producing extended-spectrum β -lactamases VEB-1 and SHV-5, metallo- β -lactamase VIM-1, and RNA methylase RmtB. <i>Journal of Global Antimicrobial Resistance</i> , 2013, 1, 115-116.	2.2	9
52	Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2388-2390.	3.2	115
53	Successful treatment of extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis with intraventricular colistin after application of a loading dose: a case series. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 480-483.	2.5	44
54	Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant <i>Acinetobacter baumannii</i> ventriculitis and meningitis: a literature review. <i>International Journal of Antimicrobial Agents</i> , 2013, 41, 499-508.	2.5	133

#	ARTICLE	IF	CITATIONS
55	Colistin Methanesulfonate and Colistin Pharmacokinetics in Critically Ill Patients Receiving Continuous Venovenous Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 668-671.	3.2	71
56	Application of a Loading Dose of Colistin Methanesulfonate in Critically Ill Patients: Population Pharmacokinetics, Protein Binding, and Prediction of Bacterial Kill. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4241-4249.	3.2	201
57	Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. <i>Journal of Critical Care</i> , 2011, 26, 331.e1-331.e7.	2.2	44
58	Acute uncomplicated cystitis: from surveillance data to a rationale for empirical treatment. <i>International Journal of Antimicrobial Agents</i> , 2010, 35, 62-67.	2.5	30
59	Population Pharmacokinetic Analysis of Colistin Methanesulfonate and Colistin after Intravenous Administration in Critically Ill Patients with Infections Caused by Gram-Negative Bacteria. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 3430-3436.	3.2	448
60	Severe dysphagia as the presenting symptom of Wernicke-Korsakoff syndrome in a non-alcoholic man. <i>Neurological Sciences</i> , 2008, 29, 45-46.	1.9	11